Medios Group Expands Medical Cannabis Access Across Germany and Europe
More patients in Germany are now accessing medical cannabis for treatment. The Medios Group has announced its entry into this growing market through a partnership with Dutch producer Bedrocan. The move aims to expand options for patients with chronic and severe conditions.
Medios will distribute Bedrocan’s medical cannabis products, sourced from a certified facility in Denmark. The focus is on the German market, where demand for reimbursable cannabis treatments is rising. Bedrocan brings over 20 years of experience, ensuring a steady supply of high-quality products.
The company has secured exclusive distribution rights in Germany, Spain, Belgium, Italy, and Austria. Support for logistics and outreach will come from Cannaflos, the Society for Medical Cannabis GmbH. This collaboration strengthens Medios’ position in a market known for its therapeutic potential, especially in oncology and neurology.
From January 2027, Medios plans to introduce additional products. These will come from new Bedrocan production sites across the five countries. The expansion reflects the company’s long-term commitment to broadening its medical cannabis portfolio.
The partnership between Medios and Bedrocan will increase access to medical cannabis for patients in Germany and beyond. With a focus on quality and reimbursable treatments, the initiative targets those with chronic illnesses. Further product launches are set to follow in the coming years.
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.
